Developing HPV virus-like particle vaccines to prevent cervical cancer: A progress report

Journal of Clinical Virology

Volumn 19, Issue 1-2, 2000, Pages 67-74

  Schiller, John T ^a   Hidesheim, Allan ^b  

^a DBS   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Human papillomaviruses; Virus like particle

Indexed keywords

UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

ANTIBODY SPECIFICITY; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; GENITAL TRACT INFECTION; IMMUNOPROPHYLAXIS; NONHUMAN; PRECANCER; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VACCINATION; VIRUS PARTICLE; WART VIRUS;

ANIMALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FEMALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES; VIRION;

EID: 0033745220     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(00)00091-3     Document Type: Article

References (42)

1. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions
2. The prevalence of HPV in cervical cancer: A worldwide perspective
3. Immunoglobulin G antibodies in human vaginal secretions after parenteral vaccination
4. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection
5. The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes
6. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes
7. Immunization with virus-like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomaviruses
8. Strategies for immunoprophylaxis and immunotherapy of papillomaviruses
9. Chimeric papillomavirus virus-like particles elicit anti-tumor immunity against the E7 oncoprotein in an HPV16 tumor model
10. Human papillomavirus (HPV) type distribution and serological response to HPV 6 virus-like particle in patients with genital warts
11. Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies
12. A population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica
13. Human papillomaviruses
14. Studies on vaccination against papillomaviruses: The immunity after infection and vaccination with bovine papillomaviruses of different types
15. Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine
16. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic
17. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization
18. A prospective study of HPV16 DNA detection by PCR and its association with aquisition and persistence of othe HPV types
19. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice
20. Human papillomavirus type 11 (HPV11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast
21. Chimeric papillomavirus-like particles
22. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice
23. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice
24. Papillomavirus-like particles can deliver defined CTL epitopes to the MHC class I pathway
25. Immunization against bovine papillomavirus infection
26. Hypothesis: Serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum
27. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype
28. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition
29. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera
30. Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies
31. Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles
32. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: Induction of cytotoxic T cells and specfic tumor protection
33. HPV DNA testing in cervical cancer screening: Results from women in a high-risk province in Costa Rica
34. Papillomavirus-like particle vaccines for cervical cancer
35. Papillomavirus-like particles: Basic and applied studies
36. Advances in vaccine adjuvants
37. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas
38. Generation and neutralization of pseudovirions of human papillomavirus type 33
39. Mucosal immunity to human papillomavirus in the female reproductive tract
40. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
41. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16
42. HPV6b virus like particles are potent immunogens without adjuvant in man